251 related articles for article (PubMed ID: 30425482)
1. From 3D spheroids to tumor bearing mice: efficacy and distribution studies of trastuzumab-docetaxel immunoliposome in breast cancer.
Rodallec A; Sicard G; Giacometti S; Carré M; Pourroy B; Bouquet F; Savina A; Lacarelle B; Ciccolini J; Fanciullino R
Int J Nanomedicine; 2018; 13():6677-6688. PubMed ID: 30425482
[TBL] [Abstract][Full Text] [Related]
2. Tumor uptake and associated greater efficacy of anti-Her2 immunoliposome does not rely on Her2 expression status: study of a docetaxel-trastuzumab immunoliposome on Her2+ breast cancer model (SKBR3).
Rodallec A; Sicard G; Giacometti S; Carre M; Maia T; Valette M; Bouquet F; Savina A; Lacarelle B; Ciccolini J; Fanciullino R
Anticancer Drugs; 2020 Jun; 31(5):463-472. PubMed ID: 31895102
[TBL] [Abstract][Full Text] [Related]
3. Docetaxel-trastuzumab stealth immunoliposome: development and in vitro proof of concept studies in breast cancer.
Rodallec A; Brunel JM; Giacometti S; Maccario H; Correard F; Mas E; Orneto C; Savina A; Bouquet F; Lacarelle B; Ciccolini J; Fanciullino R
Int J Nanomedicine; 2018; 13():3451-3465. PubMed ID: 29950829
[TBL] [Abstract][Full Text] [Related]
4. Trastuzumab emtansine (T-DM1) plus docetaxel with or without pertuzumab in patients with HER2-positive locally advanced or metastatic breast cancer: results from a phase Ib/IIa study.
Martin M; Fumoleau P; Dewar JA; Albanell J; Limentani SA; Campone M; Chang JC; Patre M; Strasak A; de Haas SL; Xu J; Garcia-Saenz JA
Ann Oncol; 2016 Jul; 27(7):1249-56. PubMed ID: 27052654
[TBL] [Abstract][Full Text] [Related]
5. Positron-Emission Tomography of HER2-Positive Breast Cancer Xenografts in Mice with
Al-Saden N; Lam K; Chan C; Reilly RM
Mol Pharm; 2018 Aug; 15(8):3383-3393. PubMed ID: 29957952
[TBL] [Abstract][Full Text] [Related]
6. Anti-HER2 immunoliposomes for co-delivery of paclitaxel and rapamycin for breast cancer therapy.
Eloy JO; Petrilli R; Chesca DL; Saggioro FP; Lee RJ; Marchetti JM
Eur J Pharm Biopharm; 2017 Jun; 115():159-167. PubMed ID: 28257810
[TBL] [Abstract][Full Text] [Related]
7. Activity of trastuzumab emtansine (T-DM1) in 3D cell culture.
Boyer JZ; Phillips GDL; Nitta H; Garsha K; Admire B; Kraft R; Dennis E; Vela E; Towne P
Breast Cancer Res Treat; 2021 Jul; 188(1):65-75. PubMed ID: 34091830
[TBL] [Abstract][Full Text] [Related]
8. Pegylated liposome encapsulating docetaxel using microfluidic mixing technique: Process optimization and results in breast cancer models.
Dacos M; Immordino B; Diroff E; Sicard G; Kosta A; Rodallec A; Giacometti S; Ciccolini J; Fanciullino R
Int J Pharm; 2024 May; 656():124091. PubMed ID: 38588758
[TBL] [Abstract][Full Text] [Related]
9. Tumor uptake and tumor/blood ratios for [
Al-Saden N; Cai Z; Reilly RM
Nucl Med Biol; 2018 Dec; 67():43-51. PubMed ID: 30390575
[TBL] [Abstract][Full Text] [Related]
10. Rapamycin-loaded Immunoliposomes Functionalized with Trastuzumab: A Strategy to Enhance Cytotoxicity to HER2-positive Breast Cancer Cells.
Eloy JO; Petrilli R; Brueggemeier RW; Marchetti JM; Lee RJ
Anticancer Agents Med Chem; 2017; 17(1):48-56. PubMed ID: 27225450
[TBL] [Abstract][Full Text] [Related]
11. Anti-HER2 immunoliposomes: enhanced efficacy attributable to targeted delivery.
Park JW; Hong K; Kirpotin DB; Colbern G; Shalaby R; Baselga J; Shao Y; Nielsen UB; Marks JD; Moore D; Papahadjopoulos D; Benz CC
Clin Cancer Res; 2002 Apr; 8(4):1172-81. PubMed ID: 11948130
[TBL] [Abstract][Full Text] [Related]
12. A Triple Combination of Metformin, Acetylsalicylic Acid, and Oseltamivir Phosphate Impacts Tumour Spheroid Viability and Upends Chemoresistance in Triple-Negative Breast Cancer.
Sambi M; Samuel V; Qorri B; Haq S; Burov SV; Markvicheva E; Harless W; Szewczuk MR
Drug Des Devel Ther; 2020; 14():1995-2019. PubMed ID: 32546966
[TBL] [Abstract][Full Text] [Related]
13. Bystander killing effect of DS-8201a, a novel anti-human epidermal growth factor receptor 2 antibody-drug conjugate, in tumors with human epidermal growth factor receptor 2 heterogeneity.
Ogitani Y; Hagihara K; Oitate M; Naito H; Agatsuma T
Cancer Sci; 2016 Jul; 107(7):1039-46. PubMed ID: 27166974
[TBL] [Abstract][Full Text] [Related]
14. [Pharmacological effects of site specific conjugated anti-human epidermal growth factor receptor 2-antibody drug conjugate using unnatural amino acid technology].
Liang XJ; Gong LY; Zhou F; Zhou DM; Zhu JJ
Beijing Da Xue Xue Bao Yi Xue Ban; 2019 Oct; 51(5):797-804. PubMed ID: 31624380
[TBL] [Abstract][Full Text] [Related]
15. Neoadjuvant trastuzumab, pertuzumab, and chemotherapy versus trastuzumab emtansine plus pertuzumab in patients with HER2-positive breast cancer (KRISTINE): a randomised, open-label, multicentre, phase 3 trial.
Hurvitz SA; Martin M; Symmans WF; Jung KH; Huang CS; Thompson AM; Harbeck N; Valero V; Stroyakovskiy D; Wildiers H; Campone M; Boileau JF; Beckmann MW; Afenjar K; Fresco R; Helms HJ; Xu J; Lin YG; Sparano J; Slamon D
Lancet Oncol; 2018 Jan; 19(1):115-126. PubMed ID: 29175149
[TBL] [Abstract][Full Text] [Related]
16.
Kwon LY; Scollard DA; Reilly RM
Mol Pharm; 2017 Feb; 14(2):492-501. PubMed ID: 28049295
[TBL] [Abstract][Full Text] [Related]
17. Loss of HER2 and decreased T-DM1 efficacy in HER2 positive advanced breast cancer treated with dual HER2 blockade: the SePHER Study.
Bon G; Pizzuti L; Laquintana V; Loria R; Porru M; Marchiò C; Krasniqi E; Barba M; Maugeri-Saccà M; Gamucci T; Berardi R; Livi L; Ficorella C; Natoli C; Cortesi E; Generali D; La Verde N; Cassano A; Bria E; Moscetti L; Michelotti A; Adamo V; Zamagni C; Tonini G; Barchiesi G; Mazzotta M; Marinelli D; Tomao S; Marchetti P; Valerio MR; Mirabelli R; Russo A; Fabbri MA; D'Ostilio N; Veltri E; Corsi D; Garrone O; Paris I; Sarobba G; Giotta F; Garufi C; Cazzaniga M; Del Medico P; Roselli M; Sanguineti G; Sperduti I; Sapino A; De Maria R; Leonetti C; Di Leo A; Ciliberto G; Falcioni R; Vici P
J Exp Clin Cancer Res; 2020 Dec; 39(1):279. PubMed ID: 33302999
[TBL] [Abstract][Full Text] [Related]
18. Trastuzumab-DM1 causes tumour growth inhibition by mitotic catastrophe in trastuzumab-resistant breast cancer cells in vivo.
Barok M; Tanner M; Köninki K; Isola J
Breast Cancer Res; 2011 Apr; 13(2):R46. PubMed ID: 21510863
[TBL] [Abstract][Full Text] [Related]
19.
Cai Z; Chattopadhyay N; Yang K; Kwon YL; Yook S; Pignol JP; Reilly RM
Nucl Med Biol; 2016 Dec; 43(12):818-826. PubMed ID: 27788375
[TBL] [Abstract][Full Text] [Related]
20. Testing chemotherapy efficacy in HER2 negative breast cancer using patient-derived spheroids.
Halfter K; Hoffmann O; Ditsch N; Ahne M; Arnold F; Paepke S; Grab D; Bauerfeind I; Mayer B
J Transl Med; 2016 May; 14(1):112. PubMed ID: 27142386
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
